Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype

Yamaki,Ei; Yajima,Toshiki; Kosaka,Takayuki; Mogi,Akira; Tanaka,Shigebumi; Kuwano,Hiroyuki

doi:10.3892/or.2013.2225

Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype

Authors:
- Ei Yamaki
- Toshiki Yajima
- Takayuki Kosaka
- Akira Mogi
- Shigebumi Tanaka
- Hiroyuki Kuwano
View Affiliations

Affiliations: Department of General Surgical Science, Gunma University Graduate School of Medicine, Gunma, Japan
Published online on: January 4, 2013 https://doi.org/10.3892/or.2013.2225
Pages: 932-940

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Podoplanin, a small type I integral membrane mucin-type sialoglycoprotein, serves as a useful marker for diagnosing malignant pleural mesothelioma (MPM); however, the physiological function of podoplanin in mesothelioma cells is not known. To elucidate the role of podoplanin in the pathogenesis of MPM, we generated two mesothelioma cell lines (PODO1 and PODO2) that stably express high levels of podoplanin. Although PODO1 cells proliferated to the same extent in culture or in nude mice, the survival rate of the mice was significantly reduced compared with that of the controls. We demonstrated that PODO1 and PODO2 cells had increased invasive ability in in vitro assays and induced upregulation of matrix metalloproteinase-1. PODO1 and PODO2 cultures could not be induced to undergo apoptosis when starved or treated with cis-diamminedichloroplatinum(II) (CDDP) compared with the controls. Moreover, silencing of podoplanin expression using RNA interference restored the ability of CDDP to induce apoptosis. Consistent with their growth properties, we detected constitutive activation of extracellular signal-regulated kinase in PODO1 and PODO2 cultures. These findings suggest that constitutive expression of podoplanin contributes to the invasive growth properties of mesothelioma cells and their resistance to apoptosis. Moreover, our data suggest that podoplanin or components of its signaling pathway, or both, may serve as important targets for developing novel treatments for MPM.

View Figures

View References

1	Fennell DA, Gaudino G, O’Byrne KJ, Mutti L and van Meerbeeck J: Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol. 5:136–147. 2008. View Article : Google Scholar : PubMed/NCBI
2	Wicki A and Christofori G: The potential role of podoplanin in tumour invasion. Br J Cancer. 96:1–5. 2007. View Article : Google Scholar : PubMed/NCBI
3	Ramirez MI, Millien G, Hinds A, Cao Y, Seldin DC and Williams MC: T1alpha, a lung type I cell differentiation gene, is required for normal lung cell proliferation and alveolus formation at birth. Dev Biol. 256:61–72. 2003. View Article : Google Scholar : PubMed/NCBI
4	Schacht V, Ramirez MI, Hong YK, et al: T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J. 22:3546–3556. 2003. View Article : Google Scholar
5	Breiteneder-Geleff S, Soleiman A, Kowalski H, et al: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 154:385–394. 1999. View Article : Google Scholar
6	Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T and Osawa M: Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol. 26:195–200. 2005. View Article : Google Scholar : PubMed/NCBI
7	Martin-Villar E, Scholl FG, Gamallo C, et al: Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer. 113:899–910. 2005. View Article : Google Scholar : PubMed/NCBI
8	Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK and Detmar M: Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 166:913–921. 2005. View Article : Google Scholar : PubMed/NCBI
9	Shibahara J, Kashima T, Kikuchi Y, Kunita A and Fukayama M: Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch. 448:493–499. 2006. View Article : Google Scholar : PubMed/NCBI
10	Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D and Christofori G: Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 9:261–272. 2006. View Article : Google Scholar : PubMed/NCBI
11	Kimura N and Kimura I: Podoplanin as a marker for mesothelioma. Pathol Int. 55:83–86. 2005. View Article : Google Scholar : PubMed/NCBI
12	Ordonez NG: Podoplanin: a novel diagnostic immunohistochemical marker. Adv Anat Pathol. 13:83–88. 2006. View Article : Google Scholar : PubMed/NCBI
13	Hinterberger M, Reineke T, Storz M, Weder W, Vogt P and Moch H: D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol. 20:248–255. 2007. View Article : Google Scholar : PubMed/NCBI
14	Padgett DM, Cathro HP, Wick MR and Mills SE: Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Am J Surg Pathol. 32:123–127. 2008. View Article : Google Scholar : PubMed/NCBI
15	Mimura T, Ito A, Sakuma T, et al: Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer. 109:933–938. 2007. View Article : Google Scholar : PubMed/NCBI
16	Marchevsky AM: Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 132:397–401. 2008.PubMed/NCBI
17	Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, et al: Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol. 26:354–360. 2008. View Article : Google Scholar : PubMed/NCBI
18	Horiguchi A, Ito K, Sumitomo M, Kimura F, Asano T and Hayakawa M: Intratumoral lymphatics and lymphatic invasion are associated with tumor aggressiveness and poor prognosis in renal cell carcinoma. Urology. 71:928–932. 2008. View Article : Google Scholar : PubMed/NCBI
19	Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T and Matsutani M: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. 111:483–488. 2006. View Article : Google Scholar : PubMed/NCBI
20	Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaro S and Quintanilla M: Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci. 119:4541–4553. 2006. View Article : Google Scholar : PubMed/NCBI
21	Kunita A, Kashima TG, Morishita Y, et al: The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol. 170:1337–1347. 2007. View Article : Google Scholar : PubMed/NCBI
22	Deroanne CF, Hamelryckx D, Ho TT, et al: Cdc42 downregulates MMP-1 expression by inhibiting the ERK1/2 pathway. J Cell Sci. 118:1173–1183. 2005. View Article : Google Scholar : PubMed/NCBI
23	Zeng ZS, Shu WP, Cohen AM and Guillem JG: Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. Clin Cancer Res. 8:144–148. 2002.PubMed/NCBI
24	Tutton MG, George ML, Eccles SA, Burton S, Swift RI and Abulafi AM: Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer. 107:541–550. 2003. View Article : Google Scholar : PubMed/NCBI
25	Klominek J, Baskin B and Hauzenberger D: Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction. Clin Exp Metastasis. 16:529–539. 1998. View Article : Google Scholar : PubMed/NCBI
26	Mueller L, Goumas FA, Himpel S, Brilloff S, Rogiers X and Broering DC: Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases. Cancer Lett. 250:329–338. 2007. View Article : Google Scholar
27	Faried A, Faried LS, Kimura H, et al: RhoA and RhoC proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitro and in vivo. Eur J Cancer. 42:1455–1465. 2006. View Article : Google Scholar : PubMed/NCBI
28	Spugnini EP, Cardillo I, Verdina A, et al: Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res. 12:6133–6143. 2006. View Article : Google Scholar : PubMed/NCBI
29	Zhong J, Gencay MM, Bubendorf L, et al: ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. J Cell Physiol. 207:540–552. 2006. View Article : Google Scholar : PubMed/NCBI
30	Gorelik E, Bere WW and Herberman RB: Role of NK cells in the antimetastatic effect of anticoagulant drugs. Int J Cancer. 33:87–94. 1984. View Article : Google Scholar : PubMed/NCBI
31	Scholl FG, Gamallo C, Vilaró S and Quintanilla M: Identification of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that induces plasma membrane extensions and increased motility in keratinocytes. J Cell Sci. 112:4601–4613. 1999.PubMed/NCBI
32	Suzuki-Inoue K, Kato Y, Inoue O, et al: Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem. 282:25993–26001. 2007. View Article : Google Scholar : PubMed/NCBI
33	Edwards JG, McLaren J, Jones JL, Waller DA and O’Byrne KJ: Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer. 88:1553–1559. 2003. View Article : Google Scholar : PubMed/NCBI
34	Baker SJ and Reddy EP: Modulation of life and death by the TNF receptor superfamily. Oncogene. 17:3261–3270. 1998. View Article : Google Scholar : PubMed/NCBI
35	Wada T and Penninger JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 23:2838–2849. 2004. View Article : Google Scholar : PubMed/NCBI
36	Lee S, Yoon S and Kim DH: A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells. Gynecol Oncol. 104:338–344. 2007. View Article : Google Scholar : PubMed/NCBI